Loading
A phase 3 trial of Elacestrant, Exemestane and Tamoxifen in advanced solid tumours, run by Stemline Therapeutics, Inc., now recruiting.
A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence is a phase 3 interventional study registered as NCT06492616 by Stemline Therapeutics, Inc., with 4220 participants planned, started 2024-09-27 and due to reach its primary completion in 2029-08. Interventions recorded: Elacestrant, Anastrozole, Letrozole, Exemestane and Tamoxifen.
Shares Menarini / Stemline, Elacestrant, Endocrine therapy (SERMs, AIs, SERDs), Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Menarini / Stemline, Elacestrant, Endocrine therapy (SERMs, AIs, SERDs) and the tag pipeline.
Shares Exemestane, Tamoxifen, Endocrine therapy (SERMs, AIs, SERDs), Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Exemestane, Tamoxifen, Endocrine therapy (SERMs, AIs, SERDs), Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Menarini / Stemline, Elacestrant, Endocrine therapy (SERMs, AIs, SERDs), Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Menarini / Stemline, Elacestrant, Endocrine therapy (SERMs, AIs, SERDs) and the tag pipeline.
Shares Exemestane, Tamoxifen, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Tamoxifen, Endocrine therapy (SERMs, AIs, SERDs), Metastatic cancer (cancer that has spread) and the tag pipeline.